The effect of aquaporin-5 knockdown on HT29 colon cancer cell proliferation and migration Y Tomita1, 2, H Dorward1, J Wrin1, RJ Vary1, ML De Ieso2, AJ.

Slides:



Advertisements
Similar presentations
Relationship Between STAT3 Inhibition and the Presence of p53 on Cyclin D1 Gene Expression in Human Breast Cancer Cell Lines Introduction STAT3 and p53.
Advertisements

Targeting of reactive oxygen species can be a potential therapeutic strategy for cancer treatment Ying-Ray Lee 1, San-Yuan Chen 2, and Hau-Ren Chen 3 1.
Products > HCC1937 Transfection Reagent (Breast Carcinoma) Altogen Biosystems offers the HCC1937 Transfection Reagent among a host of 100+ cell line specific.
Yuna Jo. Introduction Prostate cancer (PCa) continues to burden the Western world with its high rates of incidence and mortality despite the.
Products > HUVEC Transfection Reagent (Human Umbilical Vein Endothelial Cells) Altogen Biosystems offers the HUVEC Transfection Reagent among a host of.
Products > AGS Transfection Reagent (Gastric Adenocarcinoma, CRL1739) Altogen Biosystems offers the AGS Transfection Reagent among a host of 100+ cell.
Products > SK-OV-3 Transfection Reagent (Human Osteosarcoma) Altogen Biosystems offers the SK-OV-3 Transfection Reagent among a host of 100+ cell line.
Products > A431 Transfection Reagent (Epidermoid Carcinoma Cells, CRL-1555) Altogen Biosystems offers the A431 Transfection Reagent among a host of 100+
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Leila Kokabee*, Xianhui Wang, Cheryl Eifert, Douglas S. Conklin
Products > T98G Transfection Reagent (Glioblastoma Cells, CRL-1690)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
GENETIC BIOMARKERS.
Products > NCI-H1299 Transfection Reagent (Lung Adenocarcinoma)
Products > HT-1080 Transfection Reagent (Fibrosarcoma Cells)
Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells
MicroRNA-34a: a key regulator in the hallmarks of renal cell carcinoma
Products > CFPEo (HTRpC) Transfection Reagent (Trachea Epithelium)
Products > HT-29 Transfection Reagent (Colorectal Adenocarcinoma)
Products > DLD-1 Transfection Reagent (Colon Cancer, CCL-221)
Products > SK-BR-3 Transfection Reagent (Breast Adenocarcinoma)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells
Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells
Products > 4T1 Transfection Reagent (Breast Cancer Cells, CRL-2539)
Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts Lung Cancer Patient Outcome  Xiao Li, MD, Liyan Wan, MD, Jian Geng, MD, Chin-Lee.
Products > Capan-1 Transfection Reagent (Pancreatic Carcinoma)
Ke Xu, Ph.D. Putuo Hospital and Cancer Institute,
Products > LoVo Transfection Reagent (Colon Adenocarcinoma)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > BT-20 Transfection Reagent (Breast Carcinoma Cells)
Products > CT26.WT Transfection Reagent (Colon Carcinoma)
Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells
Molecular Therapy - Oncolytics
Products > HUH-7 Transfection Reagent (Liver Cancer Cells)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells
LOXL2 is required for EMT and migration in pancreas cancer
Products > MIA PaCa-2 Transfection Reagent (Pancreatic Carcinoma)
miR-133a positively regulated p53/p21 pathway.
WT1 Promotes Invasion of NSCLC via Suppression of CDH1
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
Products > A375 Transfection Reagent (Melanoma Cells, CRL-1619)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
SDHB deficiency promotes TGFβ-mediated invasion and metastasis of colorectal cancer through transcriptional repression complex SNAIL1-SMAD3/4  Haiyu Wang,
Products > KB Transfection Reagent (Mouth Epidermal Carcinoma)
UHRF1 is regulated by miR-9 in colorectal cancer
Cell Physiol Biochem 2016;39: DOI: /
Complement Factor H: A Biomarker for Progression of Cutaneous Squamous Cell Carcinoma  Pilvi M. Riihilä, Liisa M. Nissinen, Risto Ala-aho, Markku Kallajoki,
Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts Lung Cancer Patient Outcome  Xiao Li, MD, Liyan Wan, MD, Jian Geng, MD, Chin-Lee.
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
Volume 142, Issue 3, Pages e2 (March 2012)
Molecular Therapy - Nucleic Acids
Products > ZR-75-1 Transfection Reagent (Breast Carcinoma, CRL1500)
Products > NCI-H460 Transfection Reagent (Lung Carcinoma, HTB177)
Products > LNCAP Transfection Reagent (Prostate Carcinoma)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > NCI-H23 Transfection Reagent (Lung Adenocarcinoma)
Products > HCT-116 Transfection Reagent (Colon Carcinoma)
Volume 132, Issue 5, Pages (May 2007)
Products > NCI-H292 Transfection Reagent (Lung Carcinoma, CRL1848)
Products > LS-174T Transfection Reagent (Colon Adenocarcinoma)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Volume 21, Issue 11, Pages (November 2014)
Figure 1. LOC is highly expressed in NPC and predicts unfavorable prognosis. (A) Differential gene expression ... Figure 1. LOC is highly expressed.
Products > CLBPEC Transfection Reagent (Neuroblastoma Cells)
Molecular Therapy - Oncolytics
Targeting GAPLINC decreased CD44 expression and tumor growth in vivo.
Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.
Presentation transcript:

The effect of aquaporin-5 knockdown on HT29 colon cancer cell proliferation and migration Y Tomita1, 2, H Dorward1, J Wrin1, RJ Vary1, ML De Ieso2, AJ Yool2, TJ Price2, 3, JE Hardingham1,2. 1. Molecular Oncology, The Basil Hetzel Institute, The Queen Elizabeth Hospital Adelaide, SA, Australia; 2. University of Adelaide, Adelaide, SA, Australia; 3. Medical Oncology, The Queen Elizabeth Hospital, Adelaide, SA, Australia. Introduction Colorectal Cancer (CRC) CRC is a highly prevalent malignancy, accounting for 10 and 9% of malignancy cases in males and females worldwide (WHO. 2012). Systemic therapy has become the standard of care in patients at high risk of recurrence after primary surgery and those with metastatic disease, however, its potential toxicities and emergence of resistance remain problematic. Aquaporin 5 (AQP5) AQP5 is a hydrophobic integral transmembrane protein, which has a dual water and ion transporter function (Ribatti et al. 2014 & Wang et al. 2015). Expression of AQP5 is induced at early stages of CRC development (Moon et al. 2003) and it is implicated in enhanced cell proliferation and migration, features pathognomonic to tumours (Woo et al. 2008 & Jung et al. 2011). AQP5 expression in CRC correlates with histological differentiation and tumour-node-metastasis (TNM) staging (Wang et al. 2012) The aim of the project was to investigate the functional significance of AQP5 in HT29 colon cancer cell line. Specifically the objectives were; To perform RNA interference (RNAi) using small interfering RNA (siRNA) to down-regulate the expression of AQP5 To perform functional assays to assess if down-regulation of AQP5 has an effect on proliferation and/or migration Cell culture HT29 cells represents primary colon adenocarcinoma and are known to harbour multiple mutation including APC, Braf, PIK3CA, SMAD4, TP53 (Trust Sanger Institute). siRNA transfection HT29 cells were transfected with siGENOME SMARTPool AQP5 siRNA (GE Healthcare) using a reverse transfection protocol. Transfected cells were incubated for 48 hours before down-stream assays. Assessment of AQP5 expression Expression of AQP5 was examined in AQP5 siRNA transfected (AQP5 siRNA), mock transfected (MT) and untreated (UT) HT29 cells by performing quantitative Polymerase Chain Reaction (qPCR) and western blot. Circular wound healing migration assay Transfected HT29 cells in a 96-well plate were treated with mitomycin C to halt proliferation and incubated for 12 hours to achieve 100% confluency. The cell monolayer was wounded with a pipette tip and a fresh mitomycin C containing media was added. After 60-minute incubation, serial images of the scratch were captured at 0, 20 and 30 hours. Proliferation Assay Proliferation assay was performed on transfected HT29 cells in a 96-well plate, using CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega). Down-regulation of AQP5 Expression from AQP5 siRNA Transfection Figure 1: AQP5 mRNA expression after AQP5 siRNA transfection N=3, **p<0.01, ***p<0.001 Error bar represents +/- standard error of mean. AQP5 expression in siRNA transfected cells was down-regulated by 59% and 55% compared to MT and UT cells. A B Figure 2: Western blot for AQP5 A Chemiluminescent blot (A) showed discrete bands at MW 212, 56, and 28 KD corresponding to AQP5 tetramers, dimers and monomers across all the transfection types. Volume quantification and normalisation to total protein of the 3 bands combined showed AQP5 protein expression in siRNA transfected cells was down-regulated by 24% and 34% compared to MT and UT cells (B) . Migration Assay Figure 4: Circular wound healing migration assay N=9, **p<0.01 Error bar represents +/- standard error of mean. Closure of circular wound for siRNA transfected cells was delayed by 19% compared to MT and 18% compared to UT at both 20 and 30 hours. Proliferation Assay Figure 5: Proliferation assay N=5, ***p<0.001 Proliferation in siRNA transfected cells was reduced by 16 and 14% compared to MT and UT at 90 minutes. Up-regulation of AQP1 Expression from AQP5 siRNA Transfection Figure 6: AQP1 mRNA expression after AQP5 siRNA transfection N=3, **p<0.01 Error bar represents +/- standard error of mean. AQP1 expression in AQP5 siRNA transfected cells was up-regulated by 77 and 133% compared to MT and UT cells. AQP1 has been implicated in tumour angiogenesis and migration (Papadopoulos and Saadoun. 2014). AQP5 siRNA transfection of HT29 cells resulted in successful knockdown of AQP5 expression at both mRNA and protein level. Reduction in migratory and proliferative properties of transfected HT29 cells supports the role of AQP5 in tumour growth and invasion of CRC, however, the magnitude of functional alteration observed was relatively small. Lack of sufficient AQP5 knockdown may explain this and alternative silencing methods such as CRISPR is being investigated. Compensatory up-regulation of AQP1 expression was likely to have enhanced migration of the AQP5 down-regulated cells. As HT29 cells harbour multiple mutated cancer genes, a counteractive act of the intricate molecular signalling mechanisms underlying the CRC tumorigenicity is considered. Future study examining the major oncogenic signalling pathways and AQP1 during AQP5 down-regulation is suggested. ** ** Results ** *** Aims and Objectives Conclusion *** *** Methods References WHO., 2012. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence World Wide in 2012 [Online]. Jung, H. J. et al., 2011. Aquaporin-5: a marker protein for proliferation and migration of human breast cancer cells. PLoS One, 6, e28492. Ribatti, D. et al., 2014. Aquaporins in cancer. Biochim Biophys Acta, 1840, 1550-3. Wang, W. et al., 2012. Expression of AQP5 and AQP8 in human colorectal carcinoma and their clinical significance. World J Surg Oncol, 10, 242. Wang, J. et al., 2015. Aquaporins as diagnostic and therapeutic targets in cancer: How far we are? J Transl Med, 13, 96. Trust Sanger Institute., Catalogue of Somatic Mutations in Cancer [Online]. Moon, C. et al., 2003. Involvement of aquaporins in colorectal carcinogenesis. Oncogene, 22, 6699-703. Papadopoulos, M. C. et al., 2014. Key roles of aquaporins in tumor biology. Biochim Biophys Acta – Biomembranes [online]. Woo, J. et al., 2008. Overexpression of AQP5, a putative oncogene, promotes cell growth and transformation. Cancer Lett, 264, 54-62.